Corvus Pharmaceuticals, Inc.
CRVS
$15.97
$0.161.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.17M | -15.28M | -15.08M | -45.14M | -41.40M |
| Total Depreciation and Amortization | 112.00K | 105.00K | 99.00K | 92.00K | 84.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.66M | -21.20M | -18.13M | 14.49M | 14.50M |
| Change in Net Operating Assets | 3.48M | 3.58M | 1.04M | 1.72M | -1.71M |
| Cash from Operations | -34.91M | -32.80M | -32.07M | -28.83M | -28.53M |
| Capital Expenditure | -229.00K | -174.00K | -149.00K | -149.00K | -36.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 5.00K | 5.00K | 5.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -156.66M | -7.62M | -24.62M | -25.89M | -23.20M |
| Cash from Investing | -156.89M | -7.80M | -24.76M | -26.03M | -23.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 226.90M | 36.43M | 55.02M | 54.71M | 35.34M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | 13.97M |
| Cash from Financing | 226.90M | 36.43M | 55.02M | 54.71M | 49.31M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.10M | -4.16M | -1.81M | -150.00K | -2.46M |